Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR

As of June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR carries a market capitalization of 1.53T, placing it among publicly traded companies globally. Its enterprise value stands at 1.75T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR has 18.92B shares outstanding.

As of June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR trades at a trailing price-to-earnings ratio of 18.28. The price-to-sales ratio is 4.11, and the price-to-book ratio stands at 7.13.

As of June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR trades at an EV/EBITDA multiple of 15.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR trades at an EV/FCF ratio of 21.16, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.75T versus a market cap of 1.53T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 116.85, indicating elevated leverage, while an interest coverage ratio of 16.28 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR posted a return on equity (ROE) of 30.49, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 16.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.24, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.75, useful for judging operating efficiency across full business cycles. The company generates approximately 3.84M in revenue per employee across its workforce of 75,421.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.28 indicates how many times Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR recorded 14.20B in income tax expense. That works out to an effective tax rate of 17.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 79.35B, leaving 65.20B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR's stock has gained approximately 10.36% over the past 52 weeks. The 50-day moving average sits at 76.16, while the 200-day moving average is 77.18.

Over the twelve months ended June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR generated 289.72B in revenue and converted that into 65.20B in net income, yielding earnings per share of 4.40. EBITDA reached 115.75B, while operating income came in at 87.43B.

As of June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR holds 39.75B in cash and equivalents against 253.35B in total debt, resulting in a net debt position of 203.97B. Total book value stands at 214.73B, with working capital of -22.73B providing operational flexibility.

Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR produced 94.11B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -17.43B in capital expenditures, free cash flow totaled 76.68B - equivalent to 5.20 per share.

Over the twelve months ended June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR posted a gross margin of 74.75, reflecting its pricing power and cost economics. The operating margin of 30.18 and net profit margin of 22.50 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR paid dividends of 3.16 per share. The dividend payout ratio of 71.43 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.40, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.14, meaning Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR has an Altman Z-Score of 5.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.